

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/58, 9/08, 47/10	A2	(11) International Publication Number: WO 99/08684 (43) International Publication Date: 25 February 1999 (25.02.99)
(21) International Application Number: PCT/EP98/05192 (22) International Filing Date: 17 August 1998 (17.08.98) (30) Priority Data: 9717444.5 19 August 1997 (19.08.97) GB (71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): PARR, Alan, Frank [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). RIZZOLIO, Michele, Catherine [CH/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). (74) Agent: FILLER, Wendy, Anne; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: SOLUTIONS CONTAINING AZASTEROIDS (57) Abstract The present invention discloses a novel solution comprising a therapeutically effective amount of a pharmaceutically active aza steroid, polyethylene glycol, and propylene glycol. In another aspect, the present invention discloses a pharmaceutical composition comprising the solution of the invention. In another aspect, the present invention discloses a gelatin capsule filled with the composition of the present invention.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	IS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

SOLUTIONS CONTAINING AZASTEROIDS

The present invention relates to certain pharmaceutical compositions comprising 4-aza steroids and/or 6-aza steroids. In particular, the present invention
5 relates to solutions comprising a steroid 5-alpha reductase inhibitor.

Pharmaceutically active compounds can be delivered in a variety of forms, for example in a soft elastic gelatin capsule. Methods for preparation of soft gelatin capsules are well known. See, for example, J.P. Stanley, *Soft Gelatin Capsules, Ch. 13 - Part Two in: The Theory and Practice of Industrial Pharmacy*, eds. L. Lachman
10 et. al., 3 rd Ed., pp. 398-412, 1986, and W.R. Ebert, *Soft Elastic Gelatin Capsules: A Unique Dosage Form*, Pharmaceutical Technology, Vol. 1, No. 5.

The choice of excipients is important in order to ensure good solubility and good bioavailability of the pharmaceutically active compound. See for example, A. Matso, *Excipients Commonly Used in Soft Gelatin Capsules: Their Analysis and
15 Usefulness*, Novel Drug Formulation Systems and Delivery Devices International Seminar, pp. 76-81,(1991). K. Hutchison, *Encapsulation in Softgels for Pharmaceutical Advantage*, Spec. Pub. - R. Soc. Chem., Vol. 138, pp 86-97, (1993), M.S. Patel et. al., *Advances in Softgel Formulation Technology*, Manufacturing Chemist, August 1989, and I.R. Berry, *Improving Bioavailability with Soft Gelatin
20 Capsules*, Drug & Cosmetic Industry, pp. 32, 102-108, (September, 1983). Particular issues with respect to formulation of hydrophobic pharmaceutically active compounds has been described, for example in K. Hutchison, *Formulation of Softgels For Improved Oral Delivery of Hydrophobic Drugs*, Spc. Pub. - R. Soc. Chem., Vol. 161, pp 133-147 (1995).

25 Liquid filled hard gelatin capsules have also been utilized. See, for example, D. Cade et. al., *Liquid Filled and Sealed Hard Gelatin Capsules*, Drug Development and Industrial Pharmacy, 12(11-13): 2289-2300, (1986).

Aza steroids are an important class of pharmaceutically active compounds. In particular there are 4-aza steroids and 6-aza steroids known to be inhibitors of

the enzyme testosterone 5-alpha-reductase (hereinafter "5AR inhibitors"). Such compounds are thought to be useful in the treatment of benign prostatic hyperplasia, prostate cancer and other diseases. See, for example, U.S. Pat. Nos. 4,377,584 (Rasmusson et al.), 4,220,775 (Rasmusson et al.), 4,732,897 (Cainelli et al.) 4,760,071 (Rasmusson), 4,845,104 (Carlin et al.), 4,859,681 (Rasmusson), 5,302,589 (Frye et al.), 5,438,061 (Bergman et al.), 5,543,406 (Andrews et al.), 5,565,467 (Batchelor et al.), and WO 95/07926 (Batchelor et al.). One such 5AR inhibitor, finasteride, is commercially available from Merck & Co., Inc. as PROSCAR™. These pharmaceutically active compounds are not easy to dissolve.

10 These solubility challenges can affect bioavailability possibly resulting in reduced or unpredictable bioavailability.

Briefly, in one aspect, the present invention discloses a novel solution comprising a therapeutically effective amount of a pharmaceutically active aza steroid, polyethylene glycol (PEG), and propylene glycol (PG).

15 In another aspect, the present invention discloses a pharmaceutical composition comprising the solution of this invention. The composition of this invention is particularly suitable for use as a fill formulation for gelatin capsules.

In another aspect, the present invention discloses a gelatin capsule filled with the composition of the present invention.

20 The composition of this invention has improved bioavailability over standard tablets or suspensions.

Some of the steroids useful in this invention are potent teratogens. Converting the steroid from a free powder to a solution early in the manufacturing process provides a safer process. There is less risk in working with the solution than

25 with the free solid.

Also, some of these steroids are prone to oxidation. Gelatin capsule formulations can be much more resistant to oxidation due to the low oxygen permeation of typical gelatin shells. See, for example, F.S. Hom et al., *Soft Gelatin*

capsules II: Oxygen Permeability Study of Capsule Shells, J. Pharm. Sci., Vol. 64 (No. 5), pp 851-887 (1975).

Given the PEG content of the compositions of this invention, the compositions of this invention have surprisingly short drying time. This surprisingly
5 short drying time is beneficial for manufacturing because this shortens the time from manufacturing to packaging and shipping, thereby lowering manufacturing cost.

The aza steroids useful in this invention can be any pharmaceutically active aza steroid or pharmaceutically acceptable solvate thereof. Preferred classes of aza steroids are the 4-azasteroid class of 5-alpha reductase inhibitors (5AR inhibitors)
10 and the 6-aza class of 5-alpha reductase inhibitors. For example, any of the 5AR inhibitors disclosed in the above cited patents. Particularly preferred aza steroids are the 4-aza steroids. Particularly preferred 4-aza steroids include finasteride, 17-beta-N-(2,5-bis(trifluoromethyl))phenylcarbamoyl-4-aza-5-alpha-androst-1-en-3-one which is the steroid is that disclosed in U.S. Pat. No. 5,565,467 (Batchelor et al.),
15 and 17-beta-N-1-(3,4-methylenedioxy-phenyl)-cyclohexylcarbamoyl-4-aza-5-alpha-androst-1-en-3-one and 17-beta-N-(1-(p-chlorophenyl))-cyclopentylcarbamoyl-4-aza-5-alpha-androst-1-en-3-one which are both disclosed in WO 95/07926 (Batchelor et al.). These steroids can be prepared by well-known methods, for example as described in the above cited patents.

20 The aza steroid is preferably present in the range of from 0.00075 to 0.4% by weight of the solution of this invention, more preferably from 0.0075 to 0.3 % by weight of the solution of this invention.

The PEG useful in this invention preferably has an average molecular weight range of 200-600, at which PEG is in liquid state. Particularly preferred is
25 PEG with an average molecular weight of around 400 (PEG 400). Preferably, the PEG is at least 90% by weight of the solution of this invention.

The PG is preferably from 1 to 7.5% by weight of the solution of this invention, more preferably from 4 to 6% by weight of the solution.

Generally it is preferable to include in the composition a surfactant. Suitable surfactants include, polyoxyethylene(20)sorbitan monooleate (Polysorbate 80), sodium dodecyl sulfate, and dioctylsulfosuccinate sodium salt (Docusate sodium). Surfactants may be used alone or in combination. A particularly preferred surfactant is Polysorbate 80. The surfactant or surfactant mixture is preferably from 0.05 to 1.0% by weight of the composition of this invention.

It may also be useful to include an anti-oxidant in the composition. Suitable anti-oxidants include butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), and ascorbic acid. A particularly preferred anti-oxidant is butylated hydroxytoluene. Antioxidants may be used alone or in combination. The antioxidant or mixture of antioxidants is preferably from 0.001 to 0.5% by weight of the composition of this invention.

The pharmaceutical composition of the present invention is particularly useful as a fill formulation for gelatin capsules, most preferably soft gelatin capsules.

Experimental

In the following experiments, a pharmaceutically active 4-aza steroid was utilized in various solubility studies. The pharmaceutically active steroid utilized was 17-beta-N-(2,5,-bis(trifluoromethyl))phenylcarbamoyl-4-aza-5-alpha-androst-1-ene-3-one. This steroid is described in the '467 patent and can be prepared by known methods including the methods described in the '467 patent.

The solubility of the steroid was determined by suspending excess amount of the steroid in about 1 mL of various aqueous and organic media. The resulting suspension was tumbled in a Vankel® rotating water bath maintained at 25°C and protected from light. At the end of an equilibration time, usually between 1 and 12 days, excess solid was removed by filtercentrifugation through 0.22µ filters. The resulting supernatant was then assayed for steroid concentration against an external standard. The concentration of steroid in the supernatant was determined by HPLC

analyses using a Hewlett Packard 1090 Series II/M with a DOS Chem Station. The HPLC conditions are summarized below in Table 1. The results of the solubility in various aqueous media is summarized in Table 2, and in various organic media is summarized in Table 3. Table 4 summarizes the solubility in various compositions containing a complexing agent (2-hydroxypropyl-beta-cyclodextrin). Table 5 summarizes the solubility in various oils. In the following Tables and experiments, Mili Q™ plus water is a reverse osmosis water, THF is tetrahydrofuran, DMSO is dimethylsulfoxide, Labrafil™ is a mixture of unsaturated polyglycolized glycerides obtained by partial alcoholysis of corn oil or apricot kernel oil, consisting of glycerides and polyethylene glycol esters, SDS is sodium dodecyl sulfate, "model duodenum bile salts" is a mixture of sodium glycocholate, sodium glycochenodesoxycholate, sodium glycodesoxycholate, sodium taurocholate, sodium taurochenodesoxycholate, sodium taurodesoxycholate, sodium chloride, lecithin, and phosphate buffer, Tween 80 is polyoxyethylene(20)sorbitan monooleate, the PEG 400 was purchased from Union Carbide, Molesculol™ is 2-hydroxypropyl-beta-cyclodextrin, and Intralipid™ is a mixture of soy bean oil, phospholipids, glycerin USP, and water for injection. Unless stated otherwise, all % are by weight, for example, "v/v" means % by volume.

Table 1. HPLC Conditions

Column	250 x 4.6 mm Zorbax Rx C18
Mobile Phase	A. 0.1% v/v TFA B. 0.05% v/v TFA in Acetonitrile
Percent Composition	40%B-95%B in 20 minutes (10 min hold)
Flow rate	1.0 mL/minute
Detection wavelength	210/240
Oven Temperature	35°C

Table 2. Solubility in Aqueous Media

Medium	Concentration (mg/mL)
Milli Q [®] plus water	< 0.0039
0.1N HCl	< 0.0039
0.5% carboxy methylcellulose	< 0.0039
1% Labrafil [®]	highly degraded
0.02% SDS	< 0.0039
0.01% docusate sodium	< 0.0039
0.1% Tween 80	< 0.0039
0.1% Tween 80, 0.02% SDS	< 0.0039
Model duodenum bile salts	0.0386

Table 3. Solubility in Organic Media

Medium	Concentration (mg/mL)
Propylene glycol	6.21
Polyethylene glycol 400	3.27
PEG 400, 0.1% Tween 80	3.91
Propylene carbonate	6.24
Ethyl acetate	14.49
THF	225.44
Acetonitrile	7.44
Acetone	46.97
DMSO	130.40
Benzyl Alcohol	>34
Ethanol	45.59
70% aqueous ethanol	2.73
Isopropanol	29.98

5

Table 4. Solubility in 2-Hydroxypropyl- β -cyclodextrin Solutions

Medium	Concentration (mg/mL)
10% Molecusol®	0.03
20% Molecusol®	0.12
40% Molecusol®	0.79
40% Molecusol®/25% PEG400/5%PG	0.08
40% Molecusol®/50% aqueous PEG 400	0.56

Table 5. Solubility in Various Oil Base Systems

Medium	Concentration (mg/mL)
Sesame oil	0.52
Safflower oil	0.39
Soybean oil	0.44
Cottonseed oil	0.53
Corn oil	0.56
Castor oil	2.01
Olive oil	0.44
Peanut oil	0.46
Mineral oil	0.007
1% Span 20/cotton seed oil	0.62
10% benzyl alcohol/cottonseed oil	2.77
Intralipid® 20%	0.009

5 The solubility data show that these types of steroids are very difficult to dissolve. In addition, if the dissolved steroid is going to be used in a gelatin capsule, the choice of excipients needs to be acceptable excipients for use with gelatin capsule systems. Therefore, the following excipients were considered viable components for this formulation:

10

Ethanol
Propylene glycol
Polysorbate 80
Polyethylene glycol 400

15

These excipients were then further evaluated in order to discover the best formulation. The experiment was conducted using a mixture of the following components at the corresponding percentages:

5	Ethanol	0%, 5%, and 10%
	Propylene glycol	5%, 6.25%, and 7.5%
	Polysorbate 80 (Tween 80)	0%, 0.05%, and 0.1%
	Polyethylene glycol 400	QS

10 A designed experiment was then performed following the experimental design summarized in Table 6.

Table 6. Experimental Parameters

Run #	Ethanol (%)	PG (%)	Tween 80 (%)	PEG 400 (%)
1	10	5	0.1	84.9
2	10	7.5	0.1	82.4
3	10	5	0	85
4	5	7.5	0.05	87.45
5	10	7.5	0	82.5
6	10	5	0	85
7	0	7.5	0.1	92.4
8	0	7.5	0	92.5
9	10	7.5	0.1	82.4
10	0	6.25	0.05	93.7
11	5	6.25	0.1	88.65
12	0	5	0.1	94.9
13	0	6.25	0.05	93.7
14	0	5	0	95

The experimental design included 14 runs which resulted in a full quadratic equation and error detection. JMP® was used to fit the data. The solubility of the steroid in the various compositions of the designed experiment were evaluated as described above. The results are summarized in Table 7.

5

Table 7. Solubility Results

Run #	Solubility (mg/mL)
1	5.95
2	5.82
3	4.84
4	4.21
5	4.57
6	3.26
7	3.65
8	3.97
9	5.42
10	3.92
11	3.80
12	3.90
13	0.87
14	3.14

The data from the designed experiment show that increasing the concentration of ethanol and polysorbate 80 increased the solubility of the steroid. It also indicated that propylene glycol does not have a significant effect on the solubility at the studied concentrations.

The preferred compositions were then used to prepare fill formulations suitable for use in gelatin capsules. For manufacture of 0.1, 0.5, and 2.5 mg soft-gelatin capsules, propylene glycol USP was heated to 35-50°C. Then butylated

Hydroxytoluene NF is added and the mixture is stirred until dissolved. To the resulting solution was added Polyethylene glycol 400 NF and mixed. Polysorbate 80 NF was then added and mixed. Then the steroid was added and mixed, heating to 40-45°C if necessary, until dissolved. The solution was deaerated prior to
5 encapsulation.

The gelatin was prepared by blending gelatin NF, glycerin USP, and purified water USP. The resulting mixture was heated in a pressurized reactor to melt the gelatin. The gelatin was then maintained in the molten state until used for encapsulation.

10 Encapsulation was performed using a rotary die process. The heated gelatin was fed to an encapsulation machine where it entered two spreader boxes which cast the gelatin on a cooling drum, thus forming two gelatin ribbons. Each gelatin ribbon was lubricated with Fractionated Coconut Oil on the internal side and Fractionated Coconut Oil with 0.1% Lecithin NF on the external side. The
15 Fractionated Coconut Oil prevents the gelatin from sticking to equipment and the Lecithin NF prevents the capsules from sticking together after manufacture, prior to drying. The ribbons were then conveyed to the encapsulation roller. Die cavities to form the capsules are located on the circumference of the two adjacent rollers, which rotate and pull the gelatin ribbons between them. The fill solution was
20 injected, by a metered positive-displacement pump, between the gelatin ribbons forcing them to expand and fill the die cavities. As the capsules were filled, they were simultaneously shaped, sealed and cut from the gelatin ribbon by the encapsulation rollers. The capsules were then conveyed to the rotating basket dryer.

25 The capsules were dried by tumbling in a rotating basket dryer to remove sufficient moisture to allow handling. They were then transferred onto trays and allowed to dry until the moisture level of the fill solution was not more than 8% (w/w). Drying time is the time required to reach the 8% moisture level.

Batches were prepared containing 0.1, 0.5, and 2.5 mg per capsule. The compositions are summarized in Table 8.

Table 8. 0.1, 0.5, and 2.5 mg compositions

Component		Quantity per batch (kg)		
Capsule Strength (steroid mg)		0.1	0.5	2.5
Steroid		0.0006	0.003	0.015
Polyethylene Glycol 400	NF	7.420082	7.39842	7.38642
Propylene Glycol	USP	0.390	0.390	0.390
Polysorbate 80	NF	0.0078	0.0078	0.0078
Butylated Hydroxytoluene	NF	0.00078	0.00078	0.00078
Total Fill Solution per batch (kg)		7.8	7.8	7.8

5

The batches were then evaluated for drying times. The drying time for all of the PEG based compositions that were tested was only 1 day. Those skilled in the art will generally expect that soft gelatin capsules containing oil based (hydrophobic) fill material to have drying times of about 3 days, and that PEG based fill materials typically increase drying time compared to oil based compositions. Therefore, the shorter drying time of the PEG based formulation of steroid offers an advantage over typical PEG based formulations, as well as typical oil based formulations.

Those trained in the art will also recognize that although inclusion of propylene glycol in the formulation typically decreases water migration into the fill, propylene glycol typically has no significant effect on drying time. In our case however, propylene glycol results in a greater than expected decrease in drying time.

These compositions were also evaluated for relative bioavailability using standard methods. Volunteers were randomized to receive drug in either an oral solution of the present invention, a soft gelatin capsule of the present invention, or in a standard tablet. Plasma samples were collected and pharmacokinetic parameters (AUC, C_{max} , T_{max}) were compared between the treatment groups. The relative

bioavailability from the solution and soft gelatin capsule of the present invention was 80% to 90% compared to 10% to 20% for the same amount of steroid in a tablet.

The application of which this description and claims forms part may be used as a basis for priority in respect of any subsequent application. The claims of such
5 subsequent application may be directed to any novel feature or combination of features described herein and may include, by way of example and without limitation, one or more of the following claims.

Claims

What is claimed is:

- 5 1. A solution comprising a therapeutically effective amount of a pharmaceutically active aza steroid, polyethylene glycol, and propylene glycol.
2. The solution of Claim 1 wherein said steroid is a 4-aza or a 6-aza steroid.
- 10 3. The solution of Claim 2 wherein said steroid is a 17-beta-substituted carbonyl-4-azaandrost-1-en-3-one or a 17-beta-substituted carbonyl-6-azaandrost-4-en-3-one.
4. The solution of Claim 3 wherein said steroid is a 17-beta-substituted carbonyl-4-azaandrost-1-en-3-one.
- 15 5. The solution of Claim 4 wherein said steroid is 17-beta-N-(t-butyl)- carbamoyl-4-aza-5-alpha-androst-1-en-3-one, 17-beta-N-(2,5,-bis-(trifluoromethyl))phenylcarbamoyl-4-aza-5-alpha-androst-1-en-3-one, 17-beta-N-1-(3,4-methylenedioxy-phenyl)-cyclohexylcarbamoyl-4-aza-5-alpha-androst-1-en-3-one, or 17-beta-N-(1-(p-chlorophenyl))cyclopentylcarbamoyl-4-aza-5-alpha-androst-20 1-en-3-one.
6. The solution of Claim 5 wherein said steroid is 17-beta-N-(2,5,-bis(trifluoromethyl))phenylcarbamoyl-4-aza-5-alpha-androst-1-en-3-one.
- 25 7. The solution of any of claims 1 - 6 wherein said steroid is from 0.00075 % to 0.4 % by weight of said solution.

8. The solution of claim 7 wherein said steroid is from 0.0075 % to 0.3 % by weight of said solution.
9. The solution of any of claims 1 - 8 wherein said polyethylene glycol is at least 90
5 % by weight of said solution.
10. The solution of any of claims 1 - 9 wherein said polyethylene glycol has an average molecular weight of from 200 to 600.
- 10 11. The solution of any of claims 1 - 10 wherein said propylene glycol is from 1 % to 7.5 % by weight of said solution.
12. The solution of claim 11 wherein said propylene glycol is from 4 % to 6 % by weight of said solution.
- 15 13. A pharmaceutical composition comprising the solution according to any preceding claim.
14. The composition of claim 13 further comprising a surfactant.
- 20 15. The composition of claim 14 wherein said surfactant is polysorbate 80, sodium dodecyl sulfate, docusate sodium, or mixtures thereof.
16. The composition of claim 14 or 15 wherein said surfactant is from 0.05 % to 1.0
25 % by weight of said composition.
17. The composition of any of claims 13 - 16 further comprising an antioxidant.

18. The composition of claim 17 wherein said antioxidant is butylated hydroxytoluene, butylated hydroxyanisole, ascorbic acid, or mixtures thereof.
19. The composition of claim 17 or 18 wherein said antioxidant is from 0.001 % to
5 0.5 % by weight of said composition.
20. A liquid filled gelatin capsule comprising the composition according to any of claims 13 - 19.
- 10 21. The gelatin capsule of claim 20 wherein said capsule is a soft gelatin capsule.

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/58, 9/08, 47/10, 9/48	A3	(11) International Publication Number: WO 99/08684 (43) International Publication Date: 25 February 1999 (25.02.99)
(21) International Application Number: PCT/EP98/05192 (22) International Filing Date: 17 August 1998 (17.08.98) (30) Priority Data: 9717444.5 19 August 1997 (19.08.97) GB (71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): PARR, Alan, Frank [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). RIZZOLIO, Michele, Catherine [CH/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). (74) Agent: FILLER, Wendy, Anne; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> (88) Date of publication of the international search report: 10 June 1999 (10.06.99)
(54) Title: SOLUTIONS CONTAINING AZASTEROIDS (57) Abstract The present invention discloses a novel solution comprising a therapeutically effective amount of a pharmaceutically active aza steroid, polyethylene glycol, and propylene glycol. In another aspect, the present invention discloses a pharmaceutical composition comprising the solution of the invention. In another aspect, the present invention discloses a gelatin capsule filled with the composition of the present invention.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

In national Application No
PCT/EP 98/05192

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/58 A61K9/08 A61K47/10 A61K9/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 07926 A (GLAXO) 23 March 1995 cited in the application see claims 1,18,19,23-31 see page 23, line 26 - page 25, line 19 see example 580 ---	1-21
A	WO 97 11702 A (MERCK) 3 April 1997 see claims see page 12, line 29 - page 14, line 20 ---	1-21
A	WO 92 00010 A (SMITHKLINE BEECHAM) 9 January 1992 see claims 1,10,17,19 see example III ---	1-21
A	US 5 516 768 A (M. HENRY) 14 May 1996 see claims see example 1 ---	1-21
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

5 March 1999

Date of mailing of the international search report

11/03/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo-nl,
Fax: (+31-70) 340-3016

Authorized officer

Scarponi, U

INTERNATIONAL SEARCH REPORT

Int ernational Application No
PCT/EP 98/05192

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A, P	<p>WO 98 25463 A (MERCK) 18 June 1998 see claims 1,27-32 see example 9</p> <p>-----</p>	1-21

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/05192

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9507926 A	23-03-1995	AP 494 A	15-05-1996
		AT 161268 T	15-01-1998
		AT 162199 T	15-01-1998
		AU 685167 B	15-01-1998
		AU 7798094 A	03-04-1995
		AU 690925 B	07-05-1998
		AU 7875194 A	03-04-1995
		BG 100410 A	30-09-1996
		CA 2170047 A	23-03-1995
		CA 2171329 A	23-03-1995
		CN 1131424 A	18-09-1996
		CN 1134155 A	23-10-1996
		CZ 9600745 A	11-09-1996
		DE 69407422 D	29-01-1998
		DE 69407422 T	09-04-1998
		DE 69407978 D	19-02-1998
		DE 69407978 T	07-05-1998
		EP 0719277 A	03-07-1996
		EP 0719278 A	03-07-1996
		EP 0783001 A	09-07-1997
		ES 2110260 T	01-02-1998
		ES 2113127 T	16-04-1998
		FI 961231 A	15-03-1996
		FI 961232 A	15-03-1996
		GR 3025717 T	31-03-1998
		GR 3026144 T	29-05-1998
		HR 940563 A	28-02-1997
		HU 74445 A	30-12-1996
		HU 73850 A	30-09-1996
		JP 9502729 T	18-03-1997
		JP 9502731 T	18-03-1997
		NO 961080 A	15-03-1996
		NO 961085 A	22-04-1996
		NZ 274059 A	19-12-1997
		NZ 274642 A	24-11-1997
		PL 313492 A	08-07-1996
		SG 52650 A	28-09-1998
		SI 719278 T	30-06-1998
		SK 34796 A	03-07-1996
		WO 9507927 A	23-03-1995
		US 5565467 A	15-10-1996
		US 5846976 A	08-12-1998
		ZA 9407118 A	26-05-1995
		ZA 9407119 A	26-05-1995
WO 9711702 A	03-04-1997	AU 7078296 A	17-04-1997
		CA 2231434 A	03-04-1997
		EP 0859617 A	26-08-1998
WO 9200010 A	09-01-1992	US 5300294 A	05-04-1994
		AT 151635 T	15-05-1997
		AU 650033 B	09-06-1994
		AU 8207691 A	23-01-1992
		CA 2084775 A	28-12-1991
		DE 69125714 D	22-05-1997
		DE 69125714 T	23-10-1997
		DK 536282 T	27-10-1997
		EP 0536282 A	14-04-1993

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/05192

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9200010 A		ES 2100952 T GR 3024064 T JP 10081625 A JP 2702280 B US 5496556 A	01-07-1997 31-10-1997 31-03-1998 21-01-1998 05-03-1996
US 5516768 A	14-05-1996	AU 6102394 A CA 2155416 A EP 0684765 A JP 8506589 T WO 9417663 A AT 146080 T AU 648551 B AU 7573891 A CA 2076530 A DE 69123573 D DE 69123573 T EP 0521080 A WO 9113550 A	29-08-1994 18-08-1994 06-12-1995 16-07-1996 18-08-1994 15-12-1996 28-04-1994 10-10-1991 17-09-1991 23-01-1997 17-04-1997 07-01-1993 19-09-1991
WO 9825463 A	18-06-1998	AU 5369198 A	03-07-1998